AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IBRX
  4. [Form 4] ImmunityBio, Inc. Insider Trading Activity

[Form 4] ImmunityBio, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

ImmunityBio director Cheryl Cohen received a stock option grant on June 18, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:

  • Grant of 162,786 stock options to purchase common stock
  • Exercise price set at $2.84 per share
  • Options expire on June 18, 2035
  • 100% vesting occurs on the earlier of June 18, 2026 or the day before the next annual stockholder meeting
  • Vesting is contingent on continued service as defined in the 2025 Equity Incentive Plan

This grant represents standard director compensation and was filed by Jason Liljestrom as attorney-in-fact on June 20, 2025. The ownership form is listed as Direct (D), indicating Cohen holds these options personally rather than through any indirect arrangement.

Cheryl Cohen, direttrice di ImmunityBio, ha ricevuto una concessione di opzioni su azioni il 18 giugno 2025, come riportato in questo modulo Form 4. I dettagli della transazione sui titoli derivati includono:

  • Concessione di 162.786 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 2,84 $ per azione
  • Le opzioni scadono il 18 giugno 2035
  • Il 100% della maturazione avviene al pi霉 presto tra il 18 giugno 2026 o il giorno prima della prossima assemblea annuale degli azionisti
  • La maturazione 猫 subordinata alla continuazione del servizio come definito nel Piano di Incentivi Azionari 2025

Questa concessione rappresenta una compensazione standard per i direttori ed 猫 stata depositata da Jason Liljestrom in qualit脿 di procuratore il 20 giugno 2025. La forma di propriet脿 猫 indicata come Diretta (D), segnalando che Cohen detiene queste opzioni personalmente e non tramite accordi indiretti.

Cheryl Cohen, directora de ImmunityBio, recibi贸 una concesi贸n de opciones sobre acciones el 18 de junio de 2025, seg煤n se inform贸 en este formulario Form 4. Los detalles de la transacci贸n de valores derivados incluyen:

  • Concesi贸n de 162,786 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio fijado en $2.84 por acci贸n
  • Las opciones expiran el 18 de junio de 2035
  • La adquisici贸n del 100% ocurre en la fecha m谩s temprana entre el 18 de junio de 2026 o el d铆a anterior a la pr贸xima junta anual de accionistas
  • La adquisici贸n est谩 condicionada al servicio continuo seg煤n lo definido en el Plan de Incentivos de Capital 2025

Esta concesi贸n representa una compensaci贸n est谩ndar para directores y fue presentada por Jason Liljestrom como apoderado el 20 de junio de 2025. La forma de propiedad se indica como Directa (D), lo que significa que Cohen posee estas opciones personalmente y no a trav茅s de ning煤n arreglo indirecto.

ImmunityBio鞚� 鞚挫偓 Cheryl Cohen鞚� 2025雲� 6鞗� 18鞚检棎 欤检嫕毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃溂氅�, 鞚措姅 頃措嫻 Form 4 鞝滌稖靹滊鞐� 氤搓碃霅橃棃鞀惦媹雼�. 韺岇儩歃濌秾 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 162,786欤� 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $2.84搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 18鞚�
  • 100% 甓岆Μ頇曤摑鞚� 2026雲� 6鞗� 18鞚� 霕愲姅 雼れ潓 鞐半 欤检＜齑濏殞 鞝勲偁 欷� 牍犽ジ 雮犾鞐� 氚滌儩
  • 甓岆Μ頇曤摑鞚� 2025雲� 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 鞝曥潣霅� 瓿勳啀 攴茧 臁瓣贝鞐� 霐半

鞚� 攵赌鞐姅 鞚挫偓 氤挫垬鞚� 響滌 順曧儨鞚措┌, 2025雲� 6鞗� 20鞚检棎 氩曤雽�毽澑 鞛愱博鞙茧 Jason Liljestrom鞚� 鞝滌稖頃橃榾鞀惦媹雼�. 靻岇湢 順曧儨電� 歆侅爲 氤挫湢(D)搿� 氇呾嫓霅橃柎 鞛堨柎, Cohen鞚� 鞚� 鞓奠厴霌れ潉 臧滌澑鞝侅溂搿� 氤挫湢頃潉 鞚橂頃╇媹雼�.

Cheryl Cohen, administratrice de ImmunityBio, a re莽u une attribution d鈥檕ptions d鈥檃chat d鈥檃ctions le 18 juin 2025, comme indiqu茅 dans ce formulaire 4. Les d茅tails de la transaction sur titres d茅riv茅s sont les suivants :

  • Attribution de 162 786 options d鈥檃chat d鈥檃ctions pour acqu茅rir des actions ordinaires
  • Prix d鈥檈xercice fix茅 脿 2,84 $ par action
  • Les options expirent le 18 juin 2035
  • Le vesting 脿 100 % intervient 脿 la date la plus proche entre le 18 juin 2026 ou la veille de la prochaine assembl茅e annuelle des actionnaires
  • Le vesting d茅pend du maintien du service conform茅ment au Plan d鈥橧ncitation en Actions 2025

Cette attribution correspond 脿 une r茅mun茅ration standard pour les administrateurs et a 茅t茅 d茅pos茅e par Jason Liljestrom en tant que mandataire le 20 juin 2025. La forme de d茅tention est indiqu茅e comme Directe (D), signifiant que Cohen d茅tient ces options personnellement et non par le biais d鈥檜n arrangement indirect.

Cheryl Cohen, Direktorin von ImmunityBio, erhielt am 18. Juni 2025 eine Gew盲hrung von Aktienoptionen, wie in diesem Formular 4 gemeldet. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gew盲hrung von 162.786 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 2,84 $ pro Aktie
  • Die Optionen verfallen am 18. Juni 2035
  • 100%ige Vesting erfolgt am fr眉heren Datum von 18. Juni 2026 oder dem Tag vor der n盲chsten j盲hrlichen Hauptversammlung
  • Das Vesting ist an die fortgesetzte Dienstzeit gebunden, wie im Equity Incentive Plan 2025 definiert

Diese Gew盲hrung stellt eine 眉bliche Verg眉tung f眉r Direktoren dar und wurde am 20. Juni 2025 von Jason Liljestrom als Bevollm盲chtigter eingereicht. Die Besitzform ist als Direkt (D) angegeben, was bedeutet, dass Cohen diese Optionen pers枚nlich h盲lt und nicht 眉ber eine indirekte Vereinbarung.

Positive
  • Director Cheryl Cohen received a significant stock option grant of 162,786 shares at $2.84 exercise price, aligning long-term interests with shareholders through one-year cliff vesting
Negative
  • None.

Cheryl Cohen, direttrice di ImmunityBio, ha ricevuto una concessione di opzioni su azioni il 18 giugno 2025, come riportato in questo modulo Form 4. I dettagli della transazione sui titoli derivati includono:

  • Concessione di 162.786 opzioni su azioni per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 2,84 $ per azione
  • Le opzioni scadono il 18 giugno 2035
  • Il 100% della maturazione avviene al pi霉 presto tra il 18 giugno 2026 o il giorno prima della prossima assemblea annuale degli azionisti
  • La maturazione 猫 subordinata alla continuazione del servizio come definito nel Piano di Incentivi Azionari 2025

Questa concessione rappresenta una compensazione standard per i direttori ed 猫 stata depositata da Jason Liljestrom in qualit脿 di procuratore il 20 giugno 2025. La forma di propriet脿 猫 indicata come Diretta (D), segnalando che Cohen detiene queste opzioni personalmente e non tramite accordi indiretti.

Cheryl Cohen, directora de ImmunityBio, recibi贸 una concesi贸n de opciones sobre acciones el 18 de junio de 2025, seg煤n se inform贸 en este formulario Form 4. Los detalles de la transacci贸n de valores derivados incluyen:

  • Concesi贸n de 162,786 opciones sobre acciones para comprar acciones ordinarias
  • Precio de ejercicio fijado en $2.84 por acci贸n
  • Las opciones expiran el 18 de junio de 2035
  • La adquisici贸n del 100% ocurre en la fecha m谩s temprana entre el 18 de junio de 2026 o el d铆a anterior a la pr贸xima junta anual de accionistas
  • La adquisici贸n est谩 condicionada al servicio continuo seg煤n lo definido en el Plan de Incentivos de Capital 2025

Esta concesi贸n representa una compensaci贸n est谩ndar para directores y fue presentada por Jason Liljestrom como apoderado el 20 de junio de 2025. La forma de propiedad se indica como Directa (D), lo que significa que Cohen posee estas opciones personalmente y no a trav茅s de ning煤n arreglo indirecto.

ImmunityBio鞚� 鞚挫偓 Cheryl Cohen鞚� 2025雲� 6鞗� 18鞚检棎 欤检嫕毵れ垬靹犿儩甓岇潉 攵赌鞐皼鞎橃溂氅�, 鞚措姅 頃措嫻 Form 4 鞝滌稖靹滊鞐� 氤搓碃霅橃棃鞀惦媹雼�. 韺岇儩歃濌秾 瓯半灅 靹鸽秬靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 氤错喌欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 162,786欤� 欤检嫕毵れ垬靹犿儩甓� 攵赌鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $2.84搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 18鞚�
  • 100% 甓岆Μ頇曤摑鞚� 2026雲� 6鞗� 18鞚� 霕愲姅 雼れ潓 鞐半 欤检＜齑濏殞 鞝勲偁 欷� 牍犽ジ 雮犾鞐� 氚滌儩
  • 甓岆Μ頇曤摑鞚� 2025雲� 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 鞝曥潣霅� 瓿勳啀 攴茧 臁瓣贝鞐� 霐半

鞚� 攵赌鞐姅 鞚挫偓 氤挫垬鞚� 響滌 順曧儨鞚措┌, 2025雲� 6鞗� 20鞚检棎 氩曤雽�毽澑 鞛愱博鞙茧 Jason Liljestrom鞚� 鞝滌稖頃橃榾鞀惦媹雼�. 靻岇湢 順曧儨電� 歆侅爲 氤挫湢(D)搿� 氇呾嫓霅橃柎 鞛堨柎, Cohen鞚� 鞚� 鞓奠厴霌れ潉 臧滌澑鞝侅溂搿� 氤挫湢頃潉 鞚橂頃╇媹雼�.

Cheryl Cohen, administratrice de ImmunityBio, a re莽u une attribution d鈥檕ptions d鈥檃chat d鈥檃ctions le 18 juin 2025, comme indiqu茅 dans ce formulaire 4. Les d茅tails de la transaction sur titres d茅riv茅s sont les suivants :

  • Attribution de 162 786 options d鈥檃chat d鈥檃ctions pour acqu茅rir des actions ordinaires
  • Prix d鈥檈xercice fix茅 脿 2,84 $ par action
  • Les options expirent le 18 juin 2035
  • Le vesting 脿 100 % intervient 脿 la date la plus proche entre le 18 juin 2026 ou la veille de la prochaine assembl茅e annuelle des actionnaires
  • Le vesting d茅pend du maintien du service conform茅ment au Plan d鈥橧ncitation en Actions 2025

Cette attribution correspond 脿 une r茅mun茅ration standard pour les administrateurs et a 茅t茅 d茅pos茅e par Jason Liljestrom en tant que mandataire le 20 juin 2025. La forme de d茅tention est indiqu茅e comme Directe (D), signifiant que Cohen d茅tient ces options personnellement et non par le biais d鈥檜n arrangement indirect.

Cheryl Cohen, Direktorin von ImmunityBio, erhielt am 18. Juni 2025 eine Gew盲hrung von Aktienoptionen, wie in diesem Formular 4 gemeldet. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gew盲hrung von 162.786 Aktienoptionen zum Kauf von Stammaktien
  • Aus眉bungspreis festgelegt auf 2,84 $ pro Aktie
  • Die Optionen verfallen am 18. Juni 2035
  • 100%ige Vesting erfolgt am fr眉heren Datum von 18. Juni 2026 oder dem Tag vor der n盲chsten j盲hrlichen Hauptversammlung
  • Das Vesting ist an die fortgesetzte Dienstzeit gebunden, wie im Equity Incentive Plan 2025 definiert

Diese Gew盲hrung stellt eine 眉bliche Verg眉tung f眉r Direktoren dar und wurde am 20. Juni 2025 von Jason Liljestrom als Bevollm盲chtigter eingereicht. Die Besitzform ist als Direkt (D) angegeben, was bedeutet, dass Cohen diese Optionen pers枚nlich h盲lt und nicht 眉ber eine indirekte Vereinbarung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cohen Cheryl
(Last) (First) (Middle)
C/O IMMUNITYBIO, INC.
3530 JOHN HOPKINS COURT
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $2.84 06/18/2025 A 162,786 (1) 06/18/2035 Common Stock 162,786 $0 162,786 D
Explanation of Responses:
1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.
Remarks:
/s/ Jason Liljestrom, as Attorney-in-Fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options did IBRX director Cheryl Cohen receive on June 18, 2025?

Director Cheryl Cohen received 162,786 stock options with an exercise price of $2.84 per share. These options were granted on June 18, 2025, and expire on June 18, 2035.

What is the vesting schedule for IBRX director Cheryl Cohen's stock options granted in June 2025?

The stock options vest 100% on the earlier of June 18, 2026, or the day before IBRX's next annual meeting of stockholders, subject to Cohen remaining a Service Provider as defined in the company's 2025 Equity Incentive Plan.

How many IBRX shares can Cheryl Cohen purchase through her June 2025 stock options?

Cheryl Cohen can purchase 162,786 shares of IBRX common stock through these stock options at an exercise price of $2.84 per share.

When do Cheryl Cohen's IBRX stock options expire?

The stock options expire on June 18, 2035, ten years after the grant date.

What is Cheryl Cohen's role at IBRX according to the Form 4?

According to the Form 4, Cheryl Cohen serves as a Director of ImmunityBio, Inc. (IBRX). This is indicated by the 'X' marked in the Director box under the Relationship of Reporting Person(s) to Issuer section.
Stock IBRX logo
Immunitybio Inc

NASDAQ:IBRX

IBRX Rankings

#2762 Ranked by Market Cap
N/A Ranked by Dividends

IBRX Latest News

Aug 11, 2025
ImmunityBio Announces Houston鈥檚 Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA庐 to Bladder Cancer Patients
Aug 5, 2025
ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code
Jul 25, 2025
ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
Jul 25, 2025
ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates
Jul 7, 2025
UK MHRA Approves ImmunityBio鈥檚 ANKTIVA庐 Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

IBRX Latest SEC Filings

Aug 8, 2025
[8-K] ImmunityBio, Inc. Reports Material Event
Aug 5, 2025
[10-Q] ImmunityBio, Inc. Quarterly Earnings Report
Aug 5, 2025
[8-K] ImmunityBio, Inc. Reports Material Event
Jul 25, 2025
[8-K] ImmunityBio, Inc. Reports Material Event
Jun 23, 2025
[S-8] ImmunityBio, Inc. Employee Benefit Plan Registration

IBRX Stock Data

2.25B
291.04M
74.06%
9.35%
8.72%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SAN DIEGO